

RET-IN-4 biochemical

RET-IN-4

CATALOG #
AAA228442


PRODUCT SYNONYMS

RET-IN-4; RET-IN-4 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2436473-55-9
Targets&IC50	RET (V804M):1.97 nM (IC50), RET (M918T):0.99 nM (IC50), RET (WT):1.29 nM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	RET-IN-4 (compound 9; p.o.; 10-20 mg/kg; p.o.; daily; for 10 days) treatment represses tumor growth driven by KIF5B-RET-Ba/F3 cells in a dose-dependent manner[1]. Animal Model: Immunodeficient nude/nude mice bearing KIF5B-RET Ba/F3 cells[1]. Dosage: 10 mg/kg, 20 mg/kg. Administration: p.o.; daily; for 10 days. Result: The tumor growth was remarkably suppressed.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Echimidine N-oxide, CAS 41093-89-4



Structure
Echimidine N-oxide, CAS 41093-89-4

ADDITIONAL INFORMATION

Related Product Information for RET-IN-4 biochemical	RET-IN-4 is a potent, selective and orally active RET inhibitor with IC 50 s of 1.29 nM, 1.97 nM, and 0.99 nM for RET (WT), RET (V804M), and RET (M918T), respectively. RET-IN-4 exhibits better kinases selectivity against JAK2 (IC 50 of 4.4 nM) and FLT3 (IC 50 of 30.8 nM). RET-IN-4 has anticancer effects.
References	1. Houari Benamar, et al. Acetylcholinesterase inhibitory activity of pyrrolizidine alkaloids from Echium confusum Coincy. Nat Prod Res. 2017 Jun;31(11):1277-1285.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/biochemical/ret-in-4/228442>